Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase’s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol ‘TTPH.’ Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
Watertown, US
69 (est)+26%
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Key People at Tetraphase Pharmaceuticals

Patrick Gage

Patrick Gage


Tetraphase Pharmaceuticals Locations

Watertown, US

Tetraphase Pharmaceuticals Metrics

Tetraphase Pharmaceuticals Summary

Market capitalization

$157 M

Closing share price

Tetraphase Pharmaceuticals's current market capitalization is $157 M.

Tetraphase Pharmaceuticals Financials

Tetraphase Pharmaceuticals's revenue is $9.1 M in FY, 2014 which is 50.21% decrease from the previous period.
FY, 2013FY, 2014


$18.3 M$9.1 M

Operating income

$-113 M$-65.8 M

Operating expense total

$131 M$74.9 M

Net Income

$-120 M$-66.7 M

Operating cash flow

$103 M$18.3 M

    Tetraphase Pharmaceuticals Market Value History

    We estimate that Tetraphase Pharmaceuticals's current employees are approximately 6% female and 94% male.

    Tetraphase Pharmaceuticals Online Presence

    Tetraphase Pharmaceuticals News

    Tetraphase Pharmaceuticals Company Life

    You may also be interested in